Boston faces consequence of Guidant buy with second recall in two months
This article was originally published in Clinica
Executive Summary
Shares in Boston Scientific are wallowing at a near four-year low after the company this week recalled over 20,000 heart devices manufactured by Guidant due to a faulty component.